Haemonetics (HAE) Competitors $50.54 -0.61 (-1.20%) Closing price 09/19/2025 03:59 PM EasternExtended Trading$50.62 +0.08 (+0.17%) As of 09/19/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock HAE vs. DXCM, HQY, LNTH, PODD, QTRX, SIBN, PEN, ZBH, ALGN, and MMSIShould you be buying Haemonetics stock or one of its competitors? The main competitors of Haemonetics include DexCom (DXCM), HealthEquity (HQY), Lantheus (LNTH), Insulet (PODD), Quanterix (QTRX), SiBone (SIBN), Penumbra (PEN), Zimmer Biomet (ZBH), Align Technology (ALGN), and Merit Medical Systems (MMSI). These companies are all part of the "medical" sector. Haemonetics vs. Its Competitors DexCom HealthEquity Lantheus Insulet Quanterix SiBone Penumbra Zimmer Biomet Align Technology Merit Medical Systems Haemonetics (NYSE:HAE) and DexCom (NASDAQ:DXCM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment. Do institutionals and insiders believe in HAE or DXCM? 99.7% of Haemonetics shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 1.8% of Haemonetics shares are held by insiders. Comparatively, 0.3% of DexCom shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts prefer HAE or DXCM? Haemonetics presently has a consensus target price of $78.78, indicating a potential upside of 55.88%. DexCom has a consensus target price of $99.89, indicating a potential upside of 48.10%. Given Haemonetics' higher possible upside, equities analysts clearly believe Haemonetics is more favorable than DexCom.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Haemonetics 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.80DexCom 0 Sell rating(s) 5 Hold rating(s) 14 Buy rating(s) 3 Strong Buy rating(s) 2.91 Is HAE or DXCM more profitable? DexCom has a net margin of 13.29% compared to Haemonetics' net margin of 12.14%. DexCom's return on equity of 30.41% beat Haemonetics' return on equity.Company Net Margins Return on Equity Return on Assets Haemonetics12.14% 26.64% 9.32% DexCom 13.29%30.41%10.08% Does the media favor HAE or DXCM? In the previous week, DexCom had 26 more articles in the media than Haemonetics. MarketBeat recorded 32 mentions for DexCom and 6 mentions for Haemonetics. DexCom's average media sentiment score of 1.17 beat Haemonetics' score of 0.90 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Haemonetics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive DexCom 17 Very Positive mention(s) 1 Positive mention(s) 11 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, HAE or DXCM? Haemonetics has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. Comparatively, DexCom has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Which has higher valuation and earnings, HAE or DXCM? DexCom has higher revenue and earnings than Haemonetics. Haemonetics is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHaemonetics$1.36B1.79$167.68M$3.2715.45DexCom$4.03B6.56$576.20M$1.4446.84 SummaryDexCom beats Haemonetics on 13 of the 17 factors compared between the two stocks. Get Haemonetics News Delivered to You Automatically Sign up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HAE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HAE vs. The Competition Export to ExcelMetricHaemoneticsMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$2.46B$10.82B$5.79B$21.65BDividend YieldN/A1.88%5.63%3.51%P/E Ratio15.4521.2676.4829.96Price / Sales1.7932.26531.9560.86Price / Cash7.1024.5037.9224.97Price / Book3.093.4213.724.59Net Income$167.68M$210.63M$3.29B$999.97M7 Day Performance-3.24%-0.02%1.03%0.91%1 Month Performance-7.00%2.67%6.32%5.36%1 Year Performance-32.67%-9.96%81.16%14.36% Haemonetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HAEHaemonetics4.9396 of 5 stars$50.54-1.2%$78.78+55.9%-32.7%$2.46B$1.36B15.453,023High Trading VolumeDXCMDexCom4.9781 of 5 stars$75.58-0.8%$99.89+32.2%-6.2%$29.89B$4.03B52.4910,300Trending NewsOptions VolumeHQYHealthEquity4.4656 of 5 stars$93.02+0.6%$119.77+28.8%+19.3%$7.97B$1.20B56.383,120Positive NewsLNTHLantheus4.5971 of 5 stars$51.74-2.3%$89.67+73.3%-53.6%$3.60B$1.53B13.76700Trending NewsAnalyst ForecastAnalyst RevisionPODDInsulet4.5924 of 5 stars$340.29-0.4%$335.12-1.5%+39.2%$24.06B$2.07B103.433,900Positive NewsAnalyst ForecastQTRXQuanterix1.7924 of 5 stars$4.97+3.3%$11.75+136.4%-64.9%$223.50M$137.42M-2.73460Positive NewsSIBNSiBone3.7977 of 5 stars$15.14-3.6%$23.67+56.3%-7.8%$677.31M$167.18M-27.04350Positive NewsPENPenumbra4.7995 of 5 stars$263.58-3.4%$302.93+14.9%+27.4%$10.64B$1.19B70.104,500Positive NewsZBHZimmer Biomet4.9089 of 5 stars$100.90-2.1%$111.00+10.0%-5.9%$20.42B$7.68B24.5517,000Positive NewsAnalyst ForecastALGNAlign Technology4.9534 of 5 stars$131.06-0.4%$215.00+64.0%-48.9%$9.54B$4.00B22.1020,945Positive NewsMMSIMerit Medical Systems4.7696 of 5 stars$82.93-3.0%$107.00+29.0%-16.6%$5.07B$1.36B42.107,400Positive NewsHigh Trading Volume Related Companies and Tools Related Companies DexCom Alternatives HealthEquity Alternatives Lantheus Alternatives Insulet Alternatives Quanterix Alternatives SiBone Alternatives Penumbra Alternatives Zimmer Biomet Alternatives Align Technology Alternatives Merit Medical Systems Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:HAE) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Haemonetics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Haemonetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
